Khoury N, Pizzo M, Discenza C, Joy D, Tatarakis D, Todorov M
Nat Commun. 2025; 16(1):1822.
PMID: 39979268
PMC: 11842567.
DOI: 10.1038/s41467-025-57108-x.
Serri C, Piccioni M, Guarino V, Santonicola P, Cruz-Maya I, Crispi S
Int J Nanomedicine. 2025; 20():71-89.
PMID: 39802381
PMC: 11717652.
DOI: 10.2147/IJN.S481917.
Spigarelli R, Spisni E, Magalhaes M, Cabral C, Goncalves A, Saracino I
Int J Mol Sci. 2025; 26(1.
PMID: 39796096
PMC: 11720353.
DOI: 10.3390/ijms26010238.
Di Francesco V, Chua A, Bleier B, Amiji M
ACS Appl Mater Interfaces. 2024; 16(50):69103-69113.
PMID: 39655527
PMC: 11660045.
DOI: 10.1021/acsami.4c18679.
Niazi S
Int J Mol Sci. 2024; 25(18).
PMID: 39337696
PMC: 11432374.
DOI: 10.3390/ijms251810211.
Rational Design of Pectin-Chitosan Polyelectrolyte Nanoparticles for Enhanced Temozolomide Delivery in Brain Tumor Therapy.
Silantev V, Belousov A, Trukhin F, Struppul N, Shmelev M, Patlay A
Biomedicines. 2024; 12(7).
PMID: 39061967
PMC: 11273711.
DOI: 10.3390/biomedicines12071393.
Drug delivery in leptomeningeal disease: Navigating barriers and beyond.
Arshad N, Biswas N, Gill J, Kesari S, Ashili S
Drug Deliv. 2024; 31(1):2375521.
PMID: 38995190
PMC: 11249152.
DOI: 10.1080/10717544.2024.2375521.
Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders.
Niazi S, Mariam Z, Magoola M
Int J Mol Sci. 2024; 25(12).
PMID: 38928395
PMC: 11203520.
DOI: 10.3390/ijms25126683.
Intervening in the Premonitory Phase to Prevent Migraine: Prospects for Pharmacotherapy.
Karsan N, Goadsby P
CNS Drugs. 2024; 38(7):533-546.
PMID: 38822165
DOI: 10.1007/s40263-024-01091-2.
New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections.
Nau R, Seele J, Eiffert H
Antibiotics (Basel). 2024; 13(1).
PMID: 38247617
PMC: 10812395.
DOI: 10.3390/antibiotics13010058.
Blood-brain borders: a proposal to address limitations of historical blood-brain barrier terminology.
Badaut J, Ghersi-Egea J, Thorne R, Konsman J
Fluids Barriers CNS. 2024; 21(1):3.
PMID: 38183042
PMC: 10770911.
DOI: 10.1186/s12987-023-00478-5.
The Haptoglobin Response after Aneurysmal Subarachnoid Haemorrhage.
Bandyopadhyay S, Garland P, Gaastra B, Zolnourian A, Bulters D, Galea I
Int J Mol Sci. 2023; 24(23).
PMID: 38069244
PMC: 10707007.
DOI: 10.3390/ijms242316922.
Molecular Mechanisms of Migraine: Nitric Oxide Synthase and Neuropeptides.
Karsan N, Gosalia H, Goadsby P
Int J Mol Sci. 2023; 24(15).
PMID: 37569369
PMC: 10418996.
DOI: 10.3390/ijms241511993.
Quantification of nine antiretroviral drugs in cerebrospinal fluid: An approach to overcome sample collection tube adsorption.
Mykris T, Weinhold J, Winchester L, Scarsi K, Fletcher C, Podany A
J Chromatogr B Analyt Technol Biomed Life Sci. 2023; 1227:123810.
PMID: 37429153
PMC: 10529871.
DOI: 10.1016/j.jchromb.2023.123810.
Developmental changes in the extent of drug binding to rat plasma proteins.
Qiu F, Dziegielewska K, Huang Y, Habgood M, Fitzpatrick G, Saunders N
Sci Rep. 2023; 13(1):1266.
PMID: 36690711
PMC: 9870879.
DOI: 10.1038/s41598-023-28434-1.
Pharmacokinetic and Permeation Studies in Rat Brain of Natural Compounds Led to Investigate Eugenol as Direct Activator of Dopamine Release in PC12 Cells.
Pavan B, Bianchi A, Botti G, Ferraro L, Valerii M, Spisni E
Int J Mol Sci. 2023; 24(2).
PMID: 36675321
PMC: 9862186.
DOI: 10.3390/ijms24021800.
Migraine attacks are of peripheral origin: the debate goes on.
Do T, Hougaard A, Dussor G, Brennan K, Amin F
J Headache Pain. 2023; 24(1):3.
PMID: 36627561
PMC: 9830833.
DOI: 10.1186/s10194-022-01538-1.
Engineering antibody and protein therapeutics to cross the blood-brain barrier.
Zhao P, Zhang N, An Z
Antib Ther. 2022; 5(4):311-331.
PMID: 36540309
PMC: 9759110.
DOI: 10.1093/abt/tbac028.
New Oral Drugs for Migraine.
Karsan N, Goadsby P
CNS Drugs. 2022; 36(9):933-949.
PMID: 36031682
PMC: 9477894.
DOI: 10.1007/s40263-022-00948-8.
Proteomics in Multiple Sclerosis: The Perspective of the Clinician.
Sandi D, Kokas Z, Biernacki T, Bencsik K, Klivenyi P, Vecsei L
Int J Mol Sci. 2022; 23(9).
PMID: 35563559
PMC: 9100097.
DOI: 10.3390/ijms23095162.